Digital Reminiscence Therapy for Alzheimer's in Institutionalized People
- Conditions
- Alzheimer Disease
- Registration Number
- NCT06666075
- Lead Sponsor
- University of Jaén
- Brief Summary
Digital reminiscence therapy (DRT) is an innovative intervention designed to enhance the psychological health of institutionalized seniors with Alzheimer's disease. This approach utilizes digital tools to facilitate the sharing of personal memories and experiences, fostering social interaction and emotional engagement. By combining technology with therapeutic reminiscence techniques, DRT aims to stimulate cognitive function and improve mood, potentially alleviating symptoms of anxiety and depression commonly observed in this population.
Research indicates that reminiscence therapy can lead to improvements in quality of life and overall well-being for individuals with dementia. The interactive nature of digital platforms encourages participation and allows caregivers to customize content based on the individual's preferences and history. As such, DRT not only serves to strengthen the connections between seniors and their pasts but also enhances their current social interactions, promoting a sense of identity and belonging. Overall, DRT represents a promising avenue for addressing the psychological needs of older adults with Alzheimer's in institutional settings, highlighting the potential benefits of integrating technology into therapeutic practices.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 72
- People over 60 years of age.
- Confirmed diagnosis of mild or moderate Alzheimer's, where the patient still retains a certain degree of autobiographical memory.
- People institutionalized in a geriatric care center or similar.
- Level of cognitive impairment that allows understanding and basic interaction with digital tools.
- Approval and signature of informed consent by the participant or his/her legal representative, demonstrating agreement to participate in the study.
- Availability or access to devices (tablets or computers) provided by the study program or the care center.
- Diagnosis of other neurological or psychiatric conditions (such as vascular dementia, Parkinson's, or psychotic disorders) that may significantly interfere with the program's results.
- Patients in advanced stages of Alzheimer's with severe limitations in remembering autobiographical events or interacting with digital devices.
- Vision, hearing, or fine motor problems that prevent the use of electronic devices in an appropriate manner, without the possibility of adaptation or assistance.
- Individuals or legal representatives who are unable or unwilling to give informed consent.
- Behaviors that may put the participant, staff, or other residents at risk when carrying out program activities.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method The Quality of Life in Alzheimer's Disease (QoL-AD) Up to twelve weeks This Scale is a 13-item tool that measures quality of life specifically in people with Alzheimer's. Each item is scored from 1 to 4, with a higher score indicating a better perception of quality of life. Areas assessed include mood, physical well-being, relationships, and environment. A high total score suggests a positive perception of quality of life, useful for assessing the impact of psychological and therapeutic interventions.
Mini-Mental State Examination (MMSE) Up to twelve weeks The most widely used cognitive screening test to assess suspected symptoms consistent with cognitive impairment or dementia. Written test with a maximum score of 30. The cut-off point established for the MMSE defines "normal" cognitive function is generally set at 24, lower scores indicate more serious cognitive problems.
Montreal Cognitive Assessment (MoCA) Up to twelve weeks Instrument that examines the skills of attention, concentration, executive functions, memory, language, visuoconstructive abilities, calculation and orientation and the maximum score is 30.
Trail Making Test (TMT) Up to twelve weeks It is used to assess executive function. It measures timed motor and visual tasks, and is divided into two tests: Part A (TMTA), which assesses speed and psychomotor attention and requires connecting consecutively numbered circles; and Part B (TMTB), which tests executive function and requires connecting alternating circles of numbers and letters. Longer completion times indicate poor performance.
Isaacs test Up to twelve weeks Instrument used to assess verbal fluency. Participants have 60 seconds to generate as many words as possible within a given semantic category (animals, colors, fruits, and cities). The maximum score is 40 points (with a maximum of 10 per category). The higher the score, the better the level of verbal fluency.Instrument used to assess verbal fluency. Participants have 60 seconds to generate as many words as possible within a given semantic category (animals, colors, fruits, and cities). The maximum score is 40 points (with a maximum of 10 per category). The higher the score, the better the level of verbal fluency.
Hospital Anxiety and Depression Scale (HADS) Up to twelve weeks Assesses symptoms of anxiety (HADS-A) and depression (HADS-D) using 14 items (7 for each subscale), each scored from 0 to 3. Scores range from 0 to 21 for anxiety and for depression, where 0-7 is normal, 8-10 indicates possible symptoms, and 11 or higher suggests a clinical disorder. The HADS is ideal for identifying emotional symptoms in patients with mild to moderate cognitive impairment, complementing the MMSE for a comprehensive assessment of mental and emotional status.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Miguel Ángel Fernández Sevilla
🇪🇸Jaén, Spain